Clinical Trial

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Study acronym: BaxDuo-Baltic
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-29; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT07222917
Lead Sponsor AstraZeneca
Conditions Chronic Kidney Disease and Hypertension
Enrollment 218 participants
Start Date 2025-12-05
Primary Completion 2027-05-24 (estimated)
Study Completion 2027-05-24 (estimated)
Updated on ClinicalTrials.gov 2026-05-18